Regulation&Guideline(China)
Regulation&Guideline(China)
No
Regulation&GuidelineIssued byRelease timeDownload
01Technical Guideline for the Research of Human Cell Therapy and the Quality  Control of Drug ProductsCDE
2003/3/20

doc

02Considerations on “IND Application Studies and Application Materials for Cellular Therapy Products” CDE2018/3/13

doc

03
Technical Guideline for the Clinical Trial of Cellular Therapy Products Based on the Human Stem Cell and its derivatives (Draft for Comments)CDE2020/8/24

docx

04Technical Guideline for the Pharmaceutical Study and Evaluation of Gene Therapy Products (Draft for Comments)CDE2020/9/14

pdf

05Technical Guideline for the Pharmaceutical Study and Evaluation of Cell-Based Immunotherapy Products (Draft for Comments)CDE2020/9/30

pdf

06Technical Guideline for the Pharmaceutical Study and Evaluation of Genetic Transduction and Modification System (Draft for Comments)CDE2020/9/30

pdf


07Technical Guideline for the Clinical Trial of Cell-based Immunotherapy ProductsCDE2021/2/10

pdf

08Technical Guideline for the Pharmaceutical Study and Evaluation of HSC(Human Stem Cell)-Based Products (Draft for Comments)CDE2021/8/17

pdf

09Technical Guideline for the Non-clinical Study and Evaluation of Gene Therapy Products (Interim)CDE2021/12/3

pdf

10Technical Guideline for the Non-clinical Study of Gene-Modified Cellular Therapy Products (Interim)CDE2021/12/3

pdf

11Technical Guideline for the Clinical Long-Term Follow-up Study (Interim)CDE2021/12/3

pdf


12Technical Guideline for the Clinical Risk Management Plan for Marketing Application of Chimeric Antigen Receptor T cell (CAR-T) Therapy ProductsCDE2022/1/29

pdf

13Technical Guideline for the Pharmaceutical Study and Evaluation of Cell-based Immunotherapy Products (Interim)CDE2022/5/31

pdf

14Technical Guideline for the Pharmaceutical Study and Evaluation of In-vivo Gene Therapy Products (Interim)CDE2022/5/31

pdf

15Technical Guideline for the Pharmaceutical Study and Evaluation of Ex-vivo Genetic Modification System (Interim)CDE2022/5/31

pdf

16Administrative Measures for Clinical Trials of Stem Cells (Interim)

NMPA

国家卫生计生委

2015/7/20

doc

17Guidelines on the Quality Control and Preclinical Research of Drug Products Based on Stem Cells (Interim)

NMPA

国家卫生计生委

2015/7/31

doc

18Technical Guideline for the Research and Evaluation of Cellular Therapy Products (Interim)

NMPA

国家卫生计生委

2017/12/22

docx

19Good Manufacturing Practice (GMP) – Appendix for Cellular Therapy Drugs (Draft for Comments)

NMPA

国家卫生计生委

2022/1/6

docx

20Good Manufacturing Practice (GMP) – Appendix for Cellular Therapy Drugs (Draft for Comments)CFDI2019/11/28

docx

21

Good Manufacturing Practice for Cellular Therapy Products (Interim)CFDI2022/10/31

doc

22CAR-T Cell Quality Control Testing Research and Non-clinical Study Considerations中检院

NIFDC

2018/6/5

pdf

23Regulations on the Hematopoietic Stem Cell Transplantation国家卫健委2017/2/17

docx

24Regulations on the Clinical Use of the New Techniques in Biomedicine Studies (Draft for Comments)国家卫健委2019/2/26

docx

25Administrative Measures for the Clinical Research and Translational Use of Somatic Cell Therapy (Interim) (Draft for comment)国家卫健委2019/3/29

doc

26Regulations on the Transplantation of Hematopoietic Stem Cell Obtained from the Blood of the Umbilical Cord (Interim)国家卫健委2019/6/10

doc

27Proclamation of the General Instructions on Human Gene Therapy Products

国家药典委员会

ChPC

2019/6/10

pdf

28Proclamation of the Regulations on Microbial Testing Method of Cell-Based Products (Draft)

国家药典委员会

ChPC

2021/10/26

pdf

29Guideline for the Bioassay of Gene-Modified Cell Line

国家药典委员会

ChPC

2021/12/14

pdf

30Regulations on Manufacturing Quality Management for Chimeric Antigen Receptor T Cell (CAR-T cell)-based Drug Products中国医药生物技术协会

CMBA

2018/8/29

pdf

31Regulations on Supervision and Administration of  Autogenous Chimeric Antigen Receptor T Cell (CAR-T cell)-based Drug Products (Interim Regulations in Shanghai)上海市药监局2022/7/19

pdf

32Validation Technical Requirements for Rapid Sterility Testing Method of Cellular and Gene Therapy Products上海医药行业协会2022/7/28

docx